文献速递神经肿瘤神经重症

遗传与基因组改变通过癌症干细胞特异性趋化因子招募T细胞和小胶质细胞差异调控低级别胶质瘤生长

Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell-specific chemokine recruitment of T cells and microglia.
PubMed 文献 · Neuro Oncol · 2019-01-01

该研究利用一系列Nf1基因工程小鼠视神经胶质瘤模型,发现肿瘤生长差异并非源于胶质瘤干细胞(o-GSCs)的细胞自主生长特性,而是由o-GSC趋化因子表达模式差异所致。这些趋化因子差异招募T细胞和小胶质细胞,共同决定趋化因子C-C配体5(Ccl5)的表达水平,而Ccl5是驱动小鼠Nf1视神经胶质瘤生长的关键基质因子。

要点

  • Nf1视神经胶质瘤生长差异由o-GSC趋化因子表达模式决定,而非细胞自主生长特性。
  • o-GSC趋化因子差异招募T细胞和小胶质细胞,形成独特免疫微环境。
  • 该免疫微环境决定基质因子Ccl5表达水平,进而驱动肿瘤生长。

核心结论

  • 遗传和基因组改变通过o-GSC产生的趋化因子差异招募T细胞和小胶质细胞,造成小鼠低级别胶质瘤生物学异质性,并最终决定驱动肿瘤生长的基质因子表达。

研究设计与样本

  • 研究利用一系列Nf1基因工程小鼠视神经胶质瘤模型,这些模型分别代表肿瘤细胞起源、特定种系NF1基因突变及共存基因组改变等因素。
  • 从该小鼠模型集合中生成视神经胶质瘤干细胞(o-GSCs),并分析其内在生长特性及趋化因子产生能力。

主要发现

  • Nf1视神经胶质瘤生长的差异不是o-GSCs细胞自主生长特性的结果,而是o-GSC趋化因子表达独特模式所致。
  • o-GSC趋化因子差异招募T细胞和小胶质细胞,该免疫特征共同决定趋化因子C-C配体5(Ccl5)表达水平。
  • Ccl5是驱动小鼠Nf1视神经胶质瘤生长的关键基质因子。

临床怎么用

  • 提示低级别胶质瘤的生长异质性可能由肿瘤干细胞趋化因子介导的免疫微环境差异决定,靶向趋化因子招募或Ccl5通路或可成为治疗策略。

局限性

  • 研究基于Nf1基因工程小鼠模型,人类标本罕见且难以体外维持或体内异种移植,结论向人类低级别胶质瘤的外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: One of the clinical hallmarks of low-grade gliomas (LGGs) arising in children with the neurofibromatosis type 1 (NF1) cancer predisposition syndrome is significant clinical variability with respect to tumor growth, associated neurologic deficits, and response to therapy. Numerous factors could contribute to this clinical heterogeneity, including the tumor cell of origin, the specific germline NF1 gene mutation, and the coexistence of additional genomic alterations. Since human specimens are rarely acquired, and have proven difficult to maintain in vitro or as xenografts in vivo, we have developed a series of Nf1 mutant optic glioma mouse strains representing each of these contributing factors. METHODS: Optic glioma stem cells (o-GSCs) were generated from this collection of Nf1 genetically engineered mice, and analyzed for their intrinsic growth properties, as well as the production of chemokines that could differentially attract T cells and microglia. RESULTS: The observed differences in Nf1 optic glioma growth are not the result of cell autonomous growth properties of o-GSCs, but rather the unique patterns of o-GSC chemokine expression, which differentially attract T cells and microglia. This immune profile collectively dictates the levels of chemokine C-C ligand 5 (Ccl5) expression, the key stromal factor that drives murine Nf1 optic glioma growth. CONCLUSIONS: These findings reveal that genetic and genomic alterations create murine LGG biological heterogeneity through the differential recruitment of T cells and microglia by o-GSC-produced chemokines, which ultimately determine the expression of stromal factors that drive tumor growth.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Guo X, Pan Y, Gutmann DH, et al. Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell-specific chemokine recruitment of T cells and microglia. Neuro Oncol. 2019. PMID: 31111915. doi:10.1093/neuonc/noz080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。